PeptideStack
5.2kquestions
20kanswers
220users

How do I read an impurity table on a retatrutide certificate against the 98.2% headline?

Asked 12 Dec 2025Modified 4 months agoViewed 16k times
14

Stated plainly: retatrutide · 98.2%.

I have worked this out and I would like someone to find the error, because I suspect there is one.

My working so far, for the record, is below, and I am fairly sure the error is in the unit conversion rather than the algebra.

Where is my error, and what is the correct working?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

466 questions
shareeditfollowflag
PS
askedplunger_stop18k2812 Dec 2025
Thank you — the worked example is what makes this usable. – marta_okonkwo 2 days ago
8Related: the same reasoning applies to the counter-ion question. – Dr_Marek_Zielinski 8 months ago
add a comment

5 Answers

Sorted by votes
39

To be exact about it, identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
KL
answeredkirsi_lahtinen45k384 Feb 2026
Related: the same reasoning applies to the counter-ion question. – lyoph_cake 4 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
31

It helps to be literal here: the short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
DB
answeredDr_Signe_Baldursdottir46k3815 Feb 2026
25

To be exact about it, the honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

Compare purity within a single laboratory on the same method, never across laboratories.

edited 9 Mar 2026 by mz_4113 — added the placebo-arm figures

shareimprove this answerflag
M4
answeredmz_411399k25826 Feb 2026
19

Specifically, the method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

If you are ranking vendors, specify a method and have all samples tested at the same place.

edited 25 Mar 2026 by Dr_Nadia_Farsi — updated for the 2026 guidance change

shareimprove this answerflag
DF
answeredDr_Nadia_Farsi90k2589 Mar 2026
4This is the answer I was looking for three months ago. – lucia_marchetti 6 months ago
5The arithmetic checks out. I ran the same numbers and got the same result. – tabular_nums 8 months ago
add a comment
-3

Start from what the detector sees, because that tells you what the number means.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
TA
answeredtri_gly_ala48k3824 Jan 2026
Does this hold at lower concentrations, or does adsorption dominate? – seamus_brady 6 months ago
Worth flagging that this changed in 2025, so older answers on the site are out of date. – j_wierzbicki 5 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.